Acuta Capital Partners’s 4D Molecular Therapeutics FDMT Stock Holding History

Acuta Capital Partners’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.75M	Buy	+507,801	New	+$4.95M	4.71%	6
2024 Q1	–	Sell	-74,500	Closed	-$1.51M	–	40
2023 Q4	$1.51M	Buy	+74,500	New	+$980K	0.85%	29
2023 Q2	–	Sell	-104,753	Closed	-$1.8M	–	36
2023 Q1	$1.8M	Buy	+104,753	New	+$2.04M	1.33%	20
2021 Q2	–	Sell	-20,000	Closed	-$868K	–	43
2021 Q1	$868K	Hold	20,000	–	–	0.31%	42
2020 Q4	$829K	Buy	+20,000	New	+$826K	0.23%	46

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Acuta Capital Partners's FDMT Position: Q2 2026 in Review

Acuta Capital Partners opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 507,801 shares worth $6.75M. The stake represents 4.71% of the portfolio and ranks #6 among its holdings. This is a return to the name: Acuta Capital Partners previously reported a position in FDMT as recently as Q4 2023.

Acuta Capital Partners first reported a position in FDMT in Q4 2020 and has held it in 5 quarters since. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

Acuta Capital Partners held 507,801 shares of 4D Molecular Therapeutics worth $6.75M as of Q2 2026.
4D Molecular Therapeutics was a new Acuta Capital Partners position in Q2 2026.
4D Molecular Therapeutics made up 4.71% of Acuta Capital Partners's portfolio in Q2 2026, its #6 holding.
Acuta Capital Partners first reported a position in 4D Molecular Therapeutics in Q4 2020 and has held it in 5 quarters since.
157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.